Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review

Yaping Chang, Gordon H. Guyatt, Trevor Teich, Jamie L. Dawdy, Shaneela Shahid, Jessica K. Altman, Richard M. Stone, Mikkael A. Sekeres, Sudipto Mukherjee, Thomas W. LeBlanc, Gregory A. Abel, Christopher S. Hourigan, Mark R. Litzow, Laura C. Michaelis, Shabbir M.H. Alibhai, Pinkal Desai, Rena Buckstein, Janet MacEachern, Romina Brignardello-Petersen

Research output: Contribution to journalArticlepeer-review

Abstract

To compare the effectiveness and safety of intensive antileukemic therapy to less-intensive therapy in older adults with acute myeloid leukemia (AML) and intermediate or adverse cytogenetics, we searched the literature in Medline, Embase, and CENTRAL to identify relevant studies through July 2020. We reported the pooled hazard ratios (HRs), risk ratios (RRs), mean difference (MD) and their 95% confidence intervals (CIs) using random-effects metaanalyses and the certainty of evidence using the GRADE approach. Two randomized trials enrolling 529 patients and 23 observational studies enrolling 7296 patients proved eligible. The most common intensive interventions included cytarabine-based intensive chemotherapy, combination of cytarabine and anthracycline, or daunorubicin/idarubicin, and cytarabine plus idarubicin. The most common less-intensive therapies included low-dose cytarabine alone, or combined with clofarabine, azacitidine, and hypomethylating agentbased chemotherapy. Low certainty evidence suggests that patients who receive intensive versus less-intensive therapy may experience longer survival (HR 0.87; 95% CI, 0.76- 0.99), a higher probability of receiving allogeneic hematopoietic stem cell transplantation (RR 6.14; 95% CI, 4.03-9.35), fewer episodes of pneumonia (RR, 0.25; 95% CI, 0.06- 0.98), but a greater number of severe, treatment-emergent adverse events (RR, 1.34; 95% CI, 1.03-1.75), and a longer duration of intensive care unit hospitalization (MD, 6.84 days longer; 95% CI, 3.44 days longer to 10.24 days longer, very low certainty evidence). Low certainty evidence due to confounding in observational studies suggest superior overall survival without substantial treatment-emergent adverse effect of intensive antileukemic therapy over less-intensive therapy in older adults with AML who are candidates for intensive antileukemic therapy.

Original languageEnglish (US)
Article numbere0249087
JournalPloS one
Volume16
Issue number3 March
DOIs
StatePublished - Mar 2021
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review'. Together they form a unique fingerprint.

Cite this